183 related articles for article (PubMed ID: 30737998)
1. Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens.
Kohsaka S; Tatsuno K; Ueno T; Nagano M; Shinozaki-Ushiku A; Ushiku T; Takai D; Ikegami M; Kobayashi H; Kage H; Ando M; Hata K; Ueda H; Yamamoto S; Kojima S; Oseto K; Akaike K; Suehara Y; Hayashi T; Saito T; Takahashi F; Takahashi K; Takamochi K; Suzuki K; Nagayama S; Oda Y; Mimori K; Ishihara S; Yatomi Y; Nagase T; Nakajima J; Tanaka S; Fukayama M; Oda K; Nangaku M; Miyazono K; Miyagawa K; Aburatani H; Mano H
Cancer Sci; 2019 Apr; 110(4):1464-1479. PubMed ID: 30737998
[TBL] [Abstract][Full Text] [Related]
2. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.
Garcia EP; Minkovsky A; Jia Y; Ducar MD; Shivdasani P; Gong X; Ligon AH; Sholl LM; Kuo FC; MacConaill LE; Lindeman NI; Dong F
Arch Pathol Lab Med; 2017 Jun; 141(6):751-758. PubMed ID: 28557599
[TBL] [Abstract][Full Text] [Related]
3. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutational burden measurement using comprehensive genomic profiling assay.
Kage H; Kohsaka S; Tatsuno K; Ueno T; Ikegami M; Zokumasu K; Shinozaki-Ushiku A; Nagai S; Aburatani H; Mano H; Oda K
Jpn J Clin Oncol; 2022 Aug; 52(8):925-929. PubMed ID: 35482395
[TBL] [Abstract][Full Text] [Related]
5. The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing.
Cieslik M; Chugh R; Wu YM; Wu M; Brennan C; Lonigro R; Su F; Wang R; Siddiqui J; Mehra R; Cao X; Lucas D; Chinnaiyan AM; Robinson D
Genome Res; 2015 Sep; 25(9):1372-81. PubMed ID: 26253700
[TBL] [Abstract][Full Text] [Related]
6. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
[TBL] [Abstract][Full Text] [Related]
7. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
8. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
Pritchard CC; Salipante SJ; Koehler K; Smith C; Scroggins S; Wood B; Wu D; Lee MK; Dintzis S; Adey A; Liu Y; Eaton KD; Martins R; Stricker K; Margolin KA; Hoffman N; Churpek JE; Tait JF; King MC; Walsh T
J Mol Diagn; 2014 Jan; 16(1):56-67. PubMed ID: 24189654
[TBL] [Abstract][Full Text] [Related]
9. Illumina whole-genome complementary DNA-mediated annealing, selection, extension and ligation platform: assessing its performance in formalin-fixed, paraffin-embedded samples and identifying invasion pattern-related genes in oral squamous cell carcinoma.
Loudig O; Brandwein-Gensler M; Kim RS; Lin J; Isayeva T; Liu C; Segall JE; Kenny PA; Prystowsky MB
Hum Pathol; 2011 Dec; 42(12):1911-22. PubMed ID: 21683979
[TBL] [Abstract][Full Text] [Related]
10. Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer.
Wrzeszczynski KO; Felice V; Abhyankar A; Kozon L; Geiger H; Manaa D; London F; Robinson D; Fang X; Lin D; Lamendola-Essel MF; Khaira D; Dikoglu E; Emde AK; Robine N; Shah M; Arora K; Basturk O; Bhanot U; Kentsis A; Mansukhani MM; Bhagat G; Jobanputra V
J Mol Diagn; 2018 Nov; 20(6):822-835. PubMed ID: 30138725
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and clinical utility of a pan-solid tumor targeted RNA fusion panel: A single center experience.
Hindi I; Shen G; Tan Q; Cotzia P; Snuderl M; Feng X; Jour G
Exp Mol Pathol; 2020 Jun; 114():104403. PubMed ID: 32061944
[TBL] [Abstract][Full Text] [Related]
12. Canine Oncopanel: A capture-based, NGS platform for evaluating the mutational landscape and detecting putative driver mutations in canine cancers.
Wang G; Wu M; Durham AC; Mason NJ; Roth DB
Vet Comp Oncol; 2022 Mar; 20(1):91-101. PubMed ID: 34286913
[TBL] [Abstract][Full Text] [Related]
13. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
[TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts.
Levin JZ; Berger MF; Adiconis X; Rogov P; Melnikov A; Fennell T; Nusbaum C; Garraway LA; Gnirke A
Genome Biol; 2009; 10(10):R115. PubMed ID: 19835606
[TBL] [Abstract][Full Text] [Related]
15. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
16. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
Yokota T; Serizawa M; Hosokawa A; Kusafuka K; Mori K; Sugiyama T; Tsubosa Y; Koh Y
BMC Cancer; 2018 Aug; 18(1):826. PubMed ID: 30115035
[TBL] [Abstract][Full Text] [Related]
18. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing.
Ramani NS; Patel KP; Routbort MJ; Alvarez H; Broaddus R; Chen H; Rashid A; Lazar A; Lucas FAS; Yao H; Manekia J; Dang H; Barkoh BA; Medeiros LJ; Luthra R; Roy-Chowdhuri S
Arch Pathol Lab Med; 2021 Nov; 145(11):1405-1412. PubMed ID: 33493304
[TBL] [Abstract][Full Text] [Related]
19. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.
San Lucas FA; Allenson K; Bernard V; Castillo J; Kim DU; Ellis K; Ehli EA; Davies GE; Petersen JL; Li D; Wolff R; Katz M; Varadhachary G; Wistuba I; Maitra A; Alvarez H
Ann Oncol; 2016 Apr; 27(4):635-41. PubMed ID: 26681674
[TBL] [Abstract][Full Text] [Related]
20. Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.
Lazo de la Vega L; Hovelson DH; Cani AK; Liu CJ; McHugh JB; Lucas DR; Thomas DG; Patel RM; Tomlins SA
Hum Pathol; 2016 Dec; 58():161-170. PubMed ID: 27664537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
